1. Home
  2. SNAL vs RGNT Comparison

SNAL vs RGNT Comparison

Compare SNAL & RGNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Snail Inc.

SNAL

Snail Inc.

HOLD

Current Price

$5.19

Market Cap

26.6M

Sector

Technology

ML Signal

HOLD

RGNT

Regentis Biomaterials Ltd. Ordinary Shares

N/A

Current Price

$2.20

Market Cap

24.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SNAL
RGNT
Founded
2000
2004
Country
United States
Israel
Employees
N/A
8
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.6M
24.6M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
SNAL
RGNT
Price
$5.19
$2.20
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
680.8K
677.4K
Earning Date
05-08-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
120.00
N/A
EPS
N/A
N/A
Revenue
$81,225,622.00
N/A
Revenue This Year
$15.53
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.34
$1.23
52 Week High
$5.92
$15.50

Technical Indicators

Market Signals
Indicator
SNAL
RGNT
Relative Strength Index (RSI) 84.21 40.11
Support Level $0.65 $1.82
Resistance Level N/A $3.35
Average True Range (ATR) 0.50 0.45
MACD 0.36 -0.26
Stochastic Oscillator 89.42 2.74

Price Performance

Historical Comparison
SNAL
RGNT

About SNAL Snail Inc.

Snail Inc is an independent developer and publisher of interactive digital entertainment for consumers around the world, with a portfolio of premium games designed for use on a variety of platforms, including consoles, PC's, and mobile devices. The geographic presence of the company is in the United States and the International market, where the majority of its revenue comes from the United States. The Company has one operating and reportable segment. The company operates in the USA, the UK and Other Countries.

About RGNT Regentis Biomaterials Ltd. Ordinary Shares

Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.

Share on Social Networks: